Journal of the National Cancer Center最新文献

{"title":"Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study","authors":"Nilupai Abudureheiyimu ,&nbsp;Yun Wu ,&nbsp;Qing Li ,&nbsp;Pin Zhang ,&nbsp;Fei Ma ,&nbsp;Peng Yuan ,&nbsp;Yang Luo ,&nbsp;Ying Fan ,&nbsp;Shanshan Chen ,&nbsp;Ruigang Cai ,&nbsp;Qiao Li ,&nbsp;Yiqun Han ,&nbsp;Hangcheng Xu ,&nbsp;Yan Wang ,&nbsp;Jiayu Wang ,&nbsp;Binghe Xu","doi":"10.1016/j.jncc.2023.05.003","DOIUrl":"10.1016/j.jncc.2023.05.003","url":null,"abstract":"<div><h3>Background</h3><p>This study was conducted to evaluate the efficacy and safety of docetaxel/S-1 (TS) compared with docetaxel/capecitabine (TX) as a first-line treatment for advanced breast cancer.</p></div><div><h3>Methods</h3><p>Patients with advanced metastatic breast cancer were randomly divided into the TS group (n = 54) and the TX group (n = 57) for first-line chemotherapy from August 2015 to April 2019 (ClinicalTrials.org registration no. NCT02947061). Following the completion of combination therapy, patients without progression received S-1 or capecitabine maintenance treatment. The primary end point was progression-free survival (PFS).</p></div><div><h3>Results</h3><p>Among 111 enrolled patients, the median PFS did not differ significantly between the TS group and the TX group (TS vs. TX, 9.0 vs. 7.4 months, <em>P</em> = 0.365, 95% confidence interval [CI]: 0.50–1.11, hazard ratio [HR]: 0.75). There was also no statistically significant difference in median overall survival (OS) between the two groups (TS vs. TX, 40.2 vs. 41.3 months, <em>P</em> = 0.976). In addition, visceral metastasis and metastasis sites, such as the liver or lung, did not lead to a significant effect on PFS and OS. The two regimens showed no significant difference in adverse events, except hand-foot syndrome, which predominated in the TX group (38.6% vs. 7.4%, <em>P</em> = 0.001), and diarrhea (24.1% vs. 3.6%, <em>P</em> = 0.003) and elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels (14.8% vs. 3.5%, <em>P</em> = 0.049), which were more frequent in the TS group.</p></div><div><h3>Conclusions</h3><p>The TS and TX regimens demonstrated similar efficacy and safety for the first-line treatment of advanced breast cancer. The TS regimen had fewer cases of severe hand-foot syndrome than the TX regimen, representing an effective alternative option to the TX regimen. Further studies are warranted to define the efficacy and safety of this strategy in real-world settings.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 2","pages":"Pages 115-120"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46631963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intelligent oncology: The convergence of artificial intelligence and oncology","authors":"Bo Lin ,&nbsp;Zhibo Tan ,&nbsp;Yaqi Mo ,&nbsp;Xue Yang ,&nbsp;Yajie Liu ,&nbsp;Bo Xu","doi":"10.1016/j.jncc.2022.11.004","DOIUrl":"10.1016/j.jncc.2022.11.004","url":null,"abstract":"<div><p>With increasingly explored ideologies and technologies for potential applications of artificial intelligence (AI) in oncology, we here describe a holistic and structured concept termed intelligent oncology. Intelligent oncology is defined as a cross-disciplinary specialty which integrates oncology, radiology, pathology, molecular biology, multi-omics and computer sciences, aiming to promote cancer prevention, screening, early diagnosis and precision treatment. The development of intelligent oncology has been facilitated by fast AI technology development such as natural language processing, machine/deep learning, computer vision, and robotic process automation. While the concept and applications of intelligent oncology is still in its infancy, and there are still many hurdles and challenges, we are optimistic that it will play a pivotal role for the future of basic, translational and clinical oncology.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 83-91"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43602221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of the complement system sensitizes immune checkpoint blockade","authors":"Fei Shao ,&nbsp;Yannan Yang ,&nbsp;Zhimin Lu ,&nbsp;Jie He","doi":"10.1016/j.jncc.2022.11.005","DOIUrl":"10.1016/j.jncc.2022.11.005","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 4-6"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45005800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer","authors":"Hayden Ansinelli,&nbsp;Chris Gay,&nbsp;Steven Nguyen,&nbsp;Christopher M. Morrison,&nbsp;Jared R. Robbins","doi":"10.1016/j.jncc.2022.11.006","DOIUrl":"10.1016/j.jncc.2022.11.006","url":null,"abstract":"<div><p>Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a unique entity with increased responsiveness to treatment and excellent oncologic outcomes. The purpose of this narrative review is to highlight how an improved prognosis for HPV (+) tumors and an ever-increasing understanding of the risk factors, risk stratification, and areas of potential spread are shaping management options. Additionally, we aim to detail how advances in treatment technology on both the surgical and radiation fronts are facilitating the delivery of increasingly personalized and precise treatments. This review will describe key aspects of recent and currently-ongoing trials investigating the de-escalation and individualization of treatment in this patient cohort, and how they are building a foundation for distinct treatment paradigms for HPV (+) tumors. Further studies into the integration of biomarker-guided treatments combined with clinical trial enrollment will help ensure a future of personalized treatments and improved outcomes, both in terms of oncologic outcomes and toxicity, for patients with HPV (+) OPC.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 72-82"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48843987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to ‘Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas’ [Journal of the National Cancer Center, 1 (2021), 4: 153-162]","authors":"Jia Zhong ,&nbsp;Xiaoting Li ,&nbsp;Zhijie Wang ,&nbsp;Jianchun Duan ,&nbsp;Wenbin Li ,&nbsp;Minglei Zhuo ,&nbsp;Tongtong An ,&nbsp;Ziping Wang ,&nbsp;Tiantian Gu ,&nbsp;Yuyan Wang ,&nbsp;Hua Bai ,&nbsp;Yan Wang ,&nbsp;Meina Wu ,&nbsp;Zhikun Zhao ,&nbsp;Xin Yang ,&nbsp;Zhe Su ,&nbsp;Xiang Zhu ,&nbsp;Rui Wan ,&nbsp;Jianjie Li ,&nbsp;Jie Zhao ,&nbsp;Jie Wang","doi":"10.1016/j.jncc.2022.11.001","DOIUrl":"10.1016/j.jncc.2022.11.001","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Page 92"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41765416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ready for ctDNA-guided treatment decisions in colorectal cancer?","authors":"Jiaolin Zhou,&nbsp;Guole Lin","doi":"10.1016/j.jncc.2022.10.003","DOIUrl":"10.1016/j.jncc.2022.10.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 1-3"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44111835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data","authors":"Ru Chen ,&nbsp;Rongshou Zheng ,&nbsp;Siwei Zhang ,&nbsp;Shaoming Wang ,&nbsp;Kexin Sun ,&nbsp;Hongmei Zeng ,&nbsp;Li Li ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2023.01.002","DOIUrl":"10.1016/j.jncc.2023.01.002","url":null,"abstract":"<div><h3>Background</h3><p>Esophageal cancer poses a significant global burden, while its patterns and trends remain to be clarified. The aim of this study is to provide an update on the incidence and mortality rates of esophageal cancer and their trends in China based on data from the National Cancer Registry.</p></div><div><h3>Methods</h3><p>We extracted data from the National Central Cancer Registry (NCCR) of China from 2000 to 2016 and performed comprehensive quality control. We calculated age-standardized rates of China (ASR China) and world (ASR world) using the Chinese population in 2000 and the Segi's world standard population, and performed a joinpoint regression analysis to examine the trend in incidence and mortality of esophageal cancer. The annual percent change (APC) and weighted average APC (AAPC) over the entire study period were estimated to measure the changing trend. Subgroup analyses were conducted by sex, region and pathological type.</p></div><div><h3>Results</h3><p>A total of 487 eligible cancer registries were included in the data analysis and 22 registries with uninterrupted registration data were used for trend analysis. In 2016, there were an estimated of 184,500 incident cases of esophageal cancer and 142,300 deaths in China. The crude incidence, ASR China and ASR world were 25.25/100,000, 11.00/100,000 and 11.13/100,000, respectively. And the crude mortality, ASR China and ASR world were 19.38/100,000, 8.25/100,000 and 8.28/100,000, respectively. Esophageal squamous cell carcinoma (ESCC) was the most common histological type, accounting for 85.79% of all cases, followed by esophageal adenocarcinoma (EAC) (11.00%) and others (3.21%). There was a decreasing trend of ASR world in incidence and mortality during 2000–2016 with the AAPC of -4.6% (95% CI: -5.7%, -3.4%) and -4.6% (95% CI: -5.2%, -3.9%). The pattern and trend of esophageal cancer differ in sex, region and pathological type.</p></div><div><h3>Conclusions</h3><p>The burden of esophageal cancer in China remains high with sex, regional and subtype differences. The incidence and mortality of esophageal cancer have continued to decline over the past decade, which was due in part to the reductions in risk factor exposure and the implementation of screening.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 21-27"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45932408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in stage at diagnosis for liver cancer in China","authors":"Tianhao Shan ,&nbsp;Xianhui Ran ,&nbsp;Huizhang Li ,&nbsp;Guoshuang Feng ,&nbsp;Siwei Zhang ,&nbsp;Xuehong Zhang ,&nbsp;Lei Zhang ,&nbsp;Lingeng Lu ,&nbsp;Lan An ,&nbsp;Ruiying Fu ,&nbsp;Kexin Sun ,&nbsp;Shaoming Wang ,&nbsp;Ru Chen ,&nbsp;Li Li ,&nbsp;Wanqing Chen ,&nbsp;Wenqiang Wei ,&nbsp;Hongmei Zeng ,&nbsp;Jie He","doi":"10.1016/j.jncc.2022.12.002","DOIUrl":"10.1016/j.jncc.2022.12.002","url":null,"abstract":"<div><h3>Background</h3><p>The stage at diagnosis is a major factor in making treatment strategies and cancer control policies. However, the stage distribution for liver cancer in China was not well studied. In this multi-center hospital-based study, we aimed to identify the distribution and factors associated with stage at diagnosis for liver cancer in China.</p></div><div><h3>Methods</h3><p>We included patients diagnosed with primary liver cancer in 13 hospitals of 10 provinces covering various geographic and socioeconomic populations during 2016–2017 in China. The stage distribution overall, and by sex and age at diagnosis were analyzed. We used logistic regression to identify the factors associated with stage III-IV disease. We further compared these estimates with data from the USA.</p></div><div><h3>Results</h3><p>We included 2,991 patients with known stage at diagnosis in China. The proportion of patients diagnosed with stage I, II, III, and IV was 17.5%, 25.6%, 29.3%, and 27.6%, respectively. The proportion of stage III-IV cases was higher in women [65.1% vs 54.9%, adjusted odds ratio (OR) = 1.5, 95% CI: 1.2, 1.8] and those ≥ 60 years (61.6% vs 52.8%, OR = 1.4, 95% CI: 1.2, 1.6). We found an increased risk of stage III-IV among drinkers and those without a family history of cancer. Compared to the USA, our study population had a substantially higher proportion of stage III-IV cases (56.9% vs 45.6%).</p></div><div><h3>Conclusion</h3><p>The disparities in liver cancer stage at diagnosis among different populations within China, and between China and the USA, imply the necessity for improving cancer awareness and early detection for liver cancer in China.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 7-13"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46227233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and risk of lung cancer: A systematic review and dose-response meta-analysis of cohort studies","authors":"Ranran Qie ,&nbsp;Minghui Han ,&nbsp;Huang Huang ,&nbsp;Peiyuan Sun ,&nbsp;Yuting Xie ,&nbsp;Jie He ,&nbsp;Yawei Zhang","doi":"10.1016/j.jncc.2022.12.003","DOIUrl":"10.1016/j.jncc.2022.12.003","url":null,"abstract":"<div><h3>Objective</h3><p>To synthesize the knowledge about the association of total physical activity (TPA), leisure-time physical activity (LTPA), occupational physical activity (OPA) and lung cancer risk and explore the dose–response relationship between LTPA level and lung cancer.</p></div><div><h3>Methods</h3><p>PubMed and Web of Science were searched up to 17 November 2021. The summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated by random-effects or fixed-effects model. The dose–response analysis was conducted with restricted cubic splines.</p></div><div><h3>Results</h3><p>We identified 25 articles (42 cohort studies) that assessed the physical activity–lung cancer association, including 9,983,295 study participants and 85,988 incident cases of lung cancer. When comparing the highest to the lowest level of TPA and LTPA, lung cancer risk reduced 22% (RR, 0.78; 95% CI: 0.70, 0.86) and 12% (RR, 0.88; 95% CI: 0.83, 0.93), respectively. We found an approximately U-shaped association between LTPA and lung cancer (<em>P</em> _{non-linearity} &lt; 0.001), with the lowest risk at 15 metabolic equivalent of task hours per week (h/wk) of LTPA. Compared to participants with sitting occupations, lung cancer risk significantly increased among those being unemployed (RR, 1.33; 95% CI: 1.17, 1.51) or with standing occupations (RR, 1.37; 95% CI: 1.15, 1.63), but not among those with light or high OPA.</p></div><div><h3>Conclusions</h3><p>Our meta-analysis supported a protective effect of TPA and LTPA, but not OPA, on lung cancer risk. The novel finding of a U-shaped association between LTPA and lung cancer risk warrants further investigation.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 48-55"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47741497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for early-onset colorectal cancer: A large-scale Chinese cohort study","authors":"Zhe Pan ,&nbsp;Junfeng Huang ,&nbsp;Mingkai Huang ,&nbsp;Zhiyuan Yao ,&nbsp;Jiongqiang Huang ,&nbsp;Jingsong Chen ,&nbsp;Xiaoli Yu ,&nbsp;Rongchang Wang","doi":"10.1016/j.jncc.2023.01.001","DOIUrl":"10.1016/j.jncc.2023.01.001","url":null,"abstract":"<div><h3>Background</h3><p>The incidence of early-onset colorectal cancer (EOCRC) has increased globally since the early 1990s. Comprehensively examining the risk factors would be helpful for risk stratification and the development of personalized colorectal cancer screening strategies.</p></div><div><h3>Methods</h3><p>We performed a prospective study of the Chinese population aged 30–50 years to identify potential risk factors during a median follow-up of 9.1 years. We compared the distribution of demographic characteristics, lifestyle factors, dietary habits, and medical history among 222 EOCRC cases and 87,833 normal controls. Multivariate adjusted Cox hazard models were used for estimating EOCRC risks of each risk factor.</p></div><div><h3>Results</h3><p>Our final analyses indicated that participants with a higher body mass index (HR, 1.04; 95% CI:1.00,1.08), regular alcohol consumption (HR, 1.69; 95% CI: 1.12, 2.91), higher intake of fish (HR, 1.64; 95% CI: 1.01, 2.67), hypertension (HR, 1.99; 95% CI: 1.04, 3.81), diabetes (HR, 2.20; 95% CI: 1.08, 4.49), and first-degree relatives with cancer (HR, 1.70; 95% CI: 1.23, 2.36) were at higher risk of EOCRC.</p></div><div><h3>Conclusion</h3><p>We identified several modifiable as well as nonmodifiable risk factors, such as higher BMI, alcohol and fish consumption, hypertension, and diabetes, were associated with EOCRC.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 1","pages":"Pages 28-34"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45737683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}